TheiaNova is a leading brand that specializes in developing novel therapies for patients with vision disorders. Their vision is to create globally disruptive, non-surgical treatments that can provide effective solutions for patients. The brand is currently focused on developing a unique therapy that will induce therapeutic remodeling of the cornea in patients with ectatic disorders, such as keratoconus.

Keratoconus is a progressive disorder that causes thinning and weakening of the cornea, resulting in a conical shape and severe vision impairment. While current therapeutic strategies focus on addressing vision impairments through glasses and corrective lenses, or halting disease progression with corneal cross-linking, there is no cure for this disease. TheiaNova is committed to bringing their innovative therapy into the clinic to benefit patients as soon as possible.

They have built a strong foundation of research and collaboration with esteemed professors and experts in the field of ophthalmology at the University of Auckland. TheiaNova is proud to be supported by Bridgewest Ventures NZ LP, a renowned venture capital firm with significant experience in incubating and launching global innovation-led companies. They also receive support from UniServices, the research application company of Waipapa Taumata Rau, University of Auckland.

As part of the Callaghan Innovation's Technology Incubator Programme, TheiaNova is actively engaged with New Zealand's innovation agency to accelerate their growth. They are dedicated to creating sound evidence to support their therapy and prioritize the needs of patients, physicians, stakeholders, and advisors. If you have any inquiries or would like to get in touch, TheiaNova welcomes your communication